MAGNEVIST 469 MG — DIN 01989987
GADOPENTETATE DIMEGLUMINE : 469 MG · BAYER INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is MAGNEVIST?
MAGNEVIST 469 MG contains GADOPENTETATE DIMEGLUMINE : 469 MG. It is listed in the Health Canada Drug Product Database under DIN 01989987, held by BAYER INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 10-Apr-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAGNEVIST used for?
Contrast enhancement during cranial/spinal MRI in adults and children; visualization of lesions with abnormal vascularity in head (extracranial) and neck in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Gadopentetic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Gadopentetic Acid, across 3 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAYER INC | 1 | 1 | MAGNEVIST | Sourceable in Canada |
| AVIR PHARMA INC. | 1 | 0 | GADOPENTETATE DIMEGLUMINE INJECTION | No marketed DIN |
| JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | 1 | 0 | GADOPENTETATE DIMEGLUMINE INJECTION, USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 469 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 20 mL, 15 mL, and 10 mL single-dose vials packaged in individual cartons. |
| Storage | Store at 15°C to 30°C. Sensitive to light. Keep container in outer carton. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Gadopentetic Acid |
|---|---|
| ATC code | V08CA01 |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01989987 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1989987 |
| Brand name | MAGNEVIST |
| Generic / active ingredient | GADOPENTETATE DIMEGLUMINE : 469 MG |
| Market authorization holder | BAYER INC |
| Health Canada schedule | Ethical |
| ATC code | V08CA01 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08CA |
| Current status | MARKETED |
| Status date | 10-Apr-2008 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
0.2 mL/kg (0.1 mmol/kg) by intravenous injection. Rate: 10 mL/min or bolus 10 mL/15 sec. Max single dose 20 mL. Follow with 5 mL saline flush.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Chronic severe kidney insufficiency (GFR <30 mL/min/1.73m2); acute kidney injury; neonates up to 4 weeks of age; known or suspected hypersensitivity.
Warnings and precautions
Risk of Nephrogenic Systemic Fibrosis (NSF) in renal impairment. Not for intrathecal use. Potential gadolinium accumulation in brain. Risk of seizures in susceptible patients.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| GADOPENTETATE DIMEGLUMINE INJECTION | 469 MG | SOLUTION | AVIR PHARMA INC. | CANCELLED PRE MARKET | 02497883 |
| GADOPENTETATE DIMEGLUMINE INJECTION, USP | 469 MG | SOLUTION | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | CANCELLED PRE MARKET | 02431513 |
2 · Same class — other molecules in ATC V08CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Gadobutrol | GADOVIST 1.0 · PIXXOSCAN | 2 | 2 | Yes |
| Gadopentetic Acid | GADOPENTETATE DIMEGLUMINE INJECTION · GADOPENTETATE DIMEGLUMINE INJECTION, USP · MAGNEVIST | 3 | 1 | Yes |
| Gadodiamide | OMNISCAN · OMNISCAN LIQ IV 287MG/ML | 2 | 1 | Yes |
| Gadoteridol | PROHANCE | 2 | 1 | Yes |
| Gadobenic Acid | MULTIHANCE | 1 | 1 | Yes |
| Gadoteric Acid | DOTAREM | 1 | 1 | Yes |
| Gadoxetic Acid | PRIMOVIST | 1 | 1 | Yes |
| Gadoversetamide | OPTIMARK | 5 | 0 | Not in Canada |
| Gadofosveset | ABLAVAR · VASOVIST | 2 | 0 | Not in Canada |
| Mangafodipir | TESLASCAN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.